Marken Helps To Broaden Clinical Research Boundaries

The Company Goes the Extra Mile to Reach Patients Across the Globe

RESEARCH TRIANGLE PARK, North Carolina, June 22, 2016 /PRNewswire/ — As the diverse landscape for clinical trials continues to evolve, Marken implements new solutions which allow their clients to reach new patients in remote locations of the world.

Logo – http://photos.prnewswire.com/prnh/20110930/NY78064LOGO

In compliance with all relevant regulations, the company is extending its reach to areas such as Iran, Mongolia, the Azores, the South Pacific Islands and the most remote territories in Eastern Europe and Africa.  It has also demonstrated its ability to deliver into and out of cities impacted by war, labor strikes, hurricanes, volcano eruptions and earthquakes. However, moving medical supplies and biologic samples into and out of these areas comes with significant challenges which include qualifying reliable transportation, defining import and export requirements and monitoring shipments continuously until they arrive on time and within stability.

Many of the most remote territories which Marken operates in are closely tied to clinical campaigns where children and adults are in need of routine immunizations and vaccines. The World Health Organization (WHO) recently endorsed a plan to “close the immunization gap” worldwide for preventable diseases in “underserved remote areas, in deprived urban settings and in fragile states.”* Marken has assured its customers that it will always find a way to service these locations.

Recent advances in technology provide the opportunity for more patients to participate in trials, regardless of location. Likewise, the introduction of remote monitoring allows for coverage in rural areas. Marken utilizes innovative tracking technology, such as the Sentry device and Maestro software, to secure data and shipments thus making it possible to conduct clinical trials in these regions.

“At the end of the day, our focus has always been to help our clients improve patient outcomes as a supply chain solutions provider,” said Wes Wheeler, Chief Executive Officer of Marken. He further commented that Marken “is always looking ahead to the next frontier of research. We routinely work side by side with our clients to ensure continuity of their business.  However, we are especially proud to serve when they have special needs in remote locations.  We rarely, if ever, decline a challenge posed by our clients and will always do our part to keep the pace of clinical trials moving on time.”

ABOUT MARKEN

Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments, and offers a state of the art GMP-compliant depot network and logistic hubs in 43 locations worldwide. Marken’s 630 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.

* www.who.int